This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Navidea Biopharmaceuticals Inc (NAVB)

AMEX: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 32.94M 9.12M 28.64M 6.42M
Receivables 1.15M 17.60K 15.79K 2.05M
Inventories 2.23M 297.50K 821.55K 1.46M
Other Current Assets 0.00 0.00 10.63K 0.00
Total Current Assets 37.33M 10.62M 30.05M 10.23M
Property, Plant & Equipment, Gross 3.61M 2.03M 1.44M 2.37M
Accumulated Depreciation & Depletion 1.48M 1.09M 977.96K 1.85M
Property, Plant & Equipment, Net 2.13M 934.58K 463.27K 519.63K
Intangibles 136.85K 92.48K 85.42K 102.69K
Other Non-Current Assets 723.10K 327.95K 598.71K 7.42K
Total Non-Current Assets 2.99M 1.36M 1.15M 629.74K
Liabilities & Shareholder Equity
Total Assets 40.32M 11.97M 31.19M 10.86M
Accounts Payable 2.42M 1.42M 681.75K 1.52M
Short Term Debt 0.00 0.00 5.57K 0.00
Other Current Liabilities 0.00 0.00 578.99K 405.52K
Total Current Liabilities 11.29M 6.19M 3.35M 3.94M
Long Term Debt 23.57M 6.93M 6.46M 0.00
Deferred Income Taxes 0.00 0.00 0.00 0.00
Other Non-Current Liabilities 9.46M 257.12K 257.32K 2.79M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 33.04M 7.19M 6.71M 2.79M
Total Liabilities 44.33M 13.38M 10.06M 6.73M
Preferred Stock Equity 8.00 7.00 10.00 11.00
Common Stock Equity -4.01M -1.41M 21.13M 4.13M
Common Par 135.92K 113.02K 95.40K 86.32K
Additional Paid In Capital 313.11M 273.04M 266.39M 254.92M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -317.26M -274.56M -245.36M -250.87M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments 0.00 0.00 0.00 0.00
Total Capitalization 19.56M 5.52M 27.59M 4.13M
Total Equity -4.01M -1.41M 21.13M 4.13M
Total Liabilities & Stock Equity 40.32M 11.97M 31.19M 10.86M
Total Common Shares Outstanding 135.92M 113.02M 95.40M 86.32M
Preferred Shares 7.56K 6.94K 10.08K 11.00K
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 121.81M 99.06M 90.51M 80.73M
Diluted Weighted Shares Outstanding 121.81M 99.06M 90.51M 80.73M
Number of Employees 57 47 32 32
Number of Part-Time Employees 8 9 9 10
NAVB News

NAVB Navidea Biopharmaceuticals Inc

Analysts Ratings for NAVB

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET NAVB ANALYST REPORT

Brokerage Partners

NAVB Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs